Trinity Biotech plc Downgraded to “Underperform” at Zacks (TRIB)
Trinity Biotech plc (NASDAQ:TRIB) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a note issued to investors on Thursday. They currently have a $22.30 price objective on the stock. Zacks‘s price objective would suggest a potential downside of 4.94% from the company’s current price.
Shares of Trinity Biotech plc (NASDAQ:TRIB) traded down 0.98% during mid-day trading on Thursday, hitting $23.23. The stock had a trading volume of 46,047 shares. Trinity Biotech plc has a 52-week low of $18.77 and a 52-week high of $28.06. The stock’s 50-day moving average is $23.27 and its 200-day moving average is $24.64. The company has a market cap of $1.078 billion and a P/E ratio of 56.26.
Trinity Biotech plc (NASDAQ:TRIB) last released its earnings data on Tuesday, July 29th. The company reported $0.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by $0.02. The company had revenue of $26.00 million for the quarter, compared to the consensus estimate of $27.00 million. On average, analysts predict that Trinity Biotech plc will post $0.83 earnings per share for the current fiscal year.
Trinity Biotech plc (NASDAQ:TRIB) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.